{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T10:09:00Z","timestamp":1792922940541,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co\u2010transporter 2 inhibitor, in patients with type 2 diabetes mellitus (\n                      <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                      ) inadequately controlled on metformin and sitagliptin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomized, double\u2010blind study, patients with\n                      <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                      (N = 218) on metformin \u22651500 mg\/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate \u226570 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ; fasting self\u2010monitored blood glucose \u22655.6 mmol\/l (\u2265100 mg\/dl); and no volume depletion\u2013related adverse events (\n                      <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>\n                      ) within 2 weeks before dose increase. Endpoints included change in glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ) at week 26 (primary); proportion of patients achieving\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      &lt;7.0%; and changes in fasting plasma glucose (\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      ), body weight and systolic blood pressure (\n                      <jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>\n                      ). Safety was assessed using\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      reports.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 85.4% of patients were titrated to canagliflozin 300 mg or matching placebo (mean \u00b1 standard deviation time to titration 6.2 \u00b1 0.8 weeks). At week 26, canagliflozin (pooled 100 and 300 mg) demonstrated superiority in\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      reduction versus placebo (\u22120.91% vs. \u22120.01%; p &lt; 0.001). Canagliflozin provided significant reductions in\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      , body weight and\n                      <jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>\n                      compared with placebo (p &lt; 0.001). The overall\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Titrated canagliflozin significantly improved\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ,\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      , body weight and\n                      <jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>\n                      , and was generally well tolerated over 26 weeks in patients with\n                      <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                      as add\u2010on to metformin and sitagliptin.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12684","type":"journal-article","created":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T04:13:53Z","timestamp":1462853633000},"page":"812-819","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin"],"prefix":"10.1111","volume":"18","author":[{"given":"H. W.","family":"Rodbard","sequence":"first","affiliation":[{"name":"Endocrine and Metabolic Consultants  Rockville MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Seufert","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, Clinic for Internal Medicine II University Medical Center  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Aggarwal and Associates Ltd  Brampton ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cao","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fung","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alba","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12174"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.05.025"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP151126.CS"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00267.2015"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0642"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X162746"},{"key":"e_1_2_7_9_1","unstructured":"2015"},{"key":"e_1_2_7_10_1","unstructured":"2015"},{"key":"e_1_2_7_11_1","unstructured":"2015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850066"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1237"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0117-z"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2013.04.1020"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12428"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12348"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12589"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467"},{"key":"e_1_2_7_28_1","unstructured":"National Committee on Quality Assurance.The Healthcare Effectiveness Data and Information Set (HEDIS) measures2013. Available from URL:http:\/\/www.fchp.org\/providers\/resources\/hedis\u2010measures.aspxAccessed 26 May 2016."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.890925"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.05.2753"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:25:40Z","timestamp":1761873940000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/dom.12684"],"URL":"https:\/\/doi.org\/10.1111\/dom.12684","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}